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Chemically synthesized carrier-bound peptides have been used as antigens in diagnostic test systems 
(ELISA) and for raising antipeptide-specific antisera. The method oes not require prior cleavage of the 
peptides from the support used for the solid-phase synthesis. Using the same resin for both the synthesis 
and the subsequent applications t was possible to avoid expensive and time-consuming purification 
procedures and artificial recoupling to solid supports. A quick and specific ELISA-based diagnostic test 
system for HIV-specific antipeptide antibodies inhuman sera was established. In addition the carrier-bound 
peptides were shown to be potent antigens for raising antibodies in animals. 
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Introduction 
Since solid-phase peptide synthesis was intro- 
duced (Merrifield, 1963) the method has been 
established in many laboratories and the use of 
synthetic peptides has become widespread in many 
areas of the natural and medical sciences. In par- 
ticular, synthetic peptides were introduced as 
specific antigens in diagnostic test systems for the 
detection of antibodies in pathological sera (Neu- 
rathet al., 1982; Modrow and Wolf, 1986). Mono- 
specific (Lerner, 1982, Dietzschold et al., 1984; 
Kris et al., 1985) or monoclonal (Scheefers-Borchel 
et al., 1985) antisera against peptide sequences 
have been produced and used for the characteriza- 
tion and identification of native polypeptides in
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cellular and molecular systems and have proven to 
be of value in immunological test systems. With 
the expanding use of oligopeptides, the chemical 
methods for synthesis have been co siderably im- 
proved and adapted to automated systems which 
allow synthesis of peptide sequences in a relatively 
short time with high yields. The consecutive puri- 
fication steps, however, are still very expensive 
and time-consuming and require highly developed 
technical equipment for the cleavage of side-chain 
protection groups and HPLC column systems for 
purification. Peptides used in diagnostic tests such 
as ELISA (enzyme-linked immunosorbent assay) 
or RIA (radioimmunoassay) have to be coupled to 
a solid-plastic support; in a similar manner cou- 
pling to larger proteins, i.e., KLH (keyhole limpet 
hemocyanin) or BSA (bovine serum albumin), is 
necessary for antibody production. However, in 
many cases these coupling procedures cause the 
destruction of secondary structure so that the 
peptide antigens no longer correspond to the na- 
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tive form. To avoid these problems we have devel- 
oped a system in which side-chain protection 
groups are removed without the simultaneous 
cleavage of the synthesized peptide from the poly- 
styrene support. The polystyrene beads have a 
large active surface and can be directly used in 
specific and sensitive diagnostic tests and to raise 
antibodies in rabbits or other animals. 
Materials and methods 
Solid support 
A copolymer of styrene with 1% divinylbenzene 
(= 1% cross-linked polystyrene) with a diameter 
of 20-50 #m was used as the solid support for 
peptide synthesis. The benzylchloride groups of 
the resin were esterified with N-t-Boc-alanine (N- 
t-butoxycarbonyl-alanine) as the first amino acid 
of the peptide sequence in a substitution of 0.59 
mmol alanine/g resin (the resin was purchased 
from Bachem, Bubendorf, Switzerland). The N-t- 
Boc group was removed by treatment with 25% 
trifluoroacetic acid in dichloromethane for 30 min 
followed by a series of three washes with dichloro- 
methane, absolute ethanol and dichloromethane. 
The resin was dried and an equivalent of 0.5 mmol 
alanine was used for peptide synthesis. 
Seclection of peptide sequences 
HIV-l-specific proteins with diagnostic rele- 
vance (p17, p24, gp41) derived from the strain 
BH10/HTLV-III (Ratner et al., 1985) were first 
analyzed in order to identify potential antigenic 
sites. This analysis was done by using a computer 
program written for a VAX 750 (Wolf et al., 1988) 
which calculates secondary structures according to 
Chou and Fasman (1987) or Gamier et al. (1978) 
and superimposes those predictions on the values 
for local hydrophilicity (Hopp and Woods, 1981) 
and surface probability (Emini et al., 1985) or 
flexibility (Karplus and Schulz, 1985). Peptide se- 
quences with a high content of B-turns in a hydro- 
philic environment, with high values for surface 
probability and flexibility, were interpreted as 
likely candidates for antigenic sites since they 
frequently form loop-like structures at the protein 
surface. According to this analysis the following 
sequences were selected for synthesis: (i) amino 
acids 109-123 of the gag protein complex: NH 2- 
Asn-Lys-Ser-Lys-Lys-Lys-Ala-Gln-Gln-Ala-Ala-Ala- 
Asp-Thr-Gly-Ala; this sequence is part of the p17 
of the gag complex; (ii) amino acids 226-237 of 
the gag protein complex of HIV-1 (HTLV- 
III/BH10); NH2-Gly-Gln-Met-Arg-Glu-Pro-Arg- 
Gly-Ser-Asp-Ile-Ala; this sequence is part of p24 
of the gag protein complex; (iii) amino acids 




Peptides were synthesized in a 430A peptide 
synthesizer (Applied Biosystems, Weiterstadt, 
F.R.G.) using Fmoc (9-fluorenylmethyloxy- 
carbonyl)-protected amino acids (Atherton et al., 
1978); in order to complete the coupling reactions 
double-couple cycles were used for each amino 
acid. t-butyl-(Ser, Asp), t-butoxycarbonyl-(Lys) 
and 4-methoxy-2,3,6-trimethylbenzenesulfonyl 
(Arg) groups were used for side-chain protection. 
Fmoc-protected amino acids were converted to 
hydroxybenzotriazol-activated esters by treatment 
with 1.5 mmol hydroxybenzotriazol and 1.2 mmol 
diisopropylcarbodiimide/mmol amino acid for 30 
min in dimethylformamide; the subsequent cou- 
pling reaction was performed in dimethylfor- 
mamide. After the coupling reaction, Fmoc groups 
were removed with 20% piperidine in dimethylfor- 
mamide followed by a series of washes with di- 
methylformamide. All of the amino acids used 
were purchased from Bachem, Bubendorf, Switzer- 
land, chemicals were obtained from Aldrich, 
Steinheim, F.R.G. and the solvents were from 
Merck, Darmstadt, F.R.G. After synthesis ide- 
chain protecting groups were removed in TFA 
with 10% thioanisol and 10% m-cresol as 
scavengers. The resin-bound peptides were washed 
in series with an excess of dichloromethane, ethyl- 
diisopropylamide and dichloromethane and dried. 
All reaction steps are shown in Fig. 1. For 
confirmation of the amino acid sequence, the car- 
rier-bound peptides were sequenced using an Ap- 
plied Biosystems gas phase sequencer. 
ELISA tests 
The ELISA tests were conducted in a Millipore 
filtration system using 96-well plates sealed on the 
bottom with hydrophilic membrane (GV) (pore 
diameter 0.2 /~m), which has a very low protein 
binding capacity (Millititersystem, Millipore, 
Eschborn, F.R.G.). The resin-bound peptides were 
suspended in PBS containing 0.1% Tween 20 and 
differing amounts (10 ng to 10/~g) of resin-bound 
pept~de were added to the wells. The beads were 
washed four times with 100 /~1 PBS/0.1% Tween 
20 and incubated 1 h in a solution of 5 mg 
gelatine in H~O and washed again. HIV-l-positive 
and -negative human sera were diluted in 
PBS/0.1% Tween 20/1% rabbit serum. 100 ~1 of 
each dilution were added and incubated with the 
resin-bound peptide for 1 h. The beads were 
washed four times with PBS/0.1% Tween 20, in- 
cubated with rabbit anti-human IgG (Dako, di- 
luted 1/1000 in PBS/0.1% Tween 20) for an 
additional hour followed by four washes in 
PBS/0.1% Tween 20. For color development, 100 
/zl phosphate buffer pH 6.0 containing 0.5 mg/ml  
o-phenylenediamine and 0.1% H~O~ were added 
for 2 min. The solution was then transferred to a 
96-well ELISA plate (Dynatech), each well con- 
taining 100 F1 1 M H~SO4 to stop the color 
reaction. Optical densities were determined at 486 
nm. In order to demonstrate peptide-antibody re- 
action, p226-237/p24 beads were incubated with 
HIV-positive serum (diluted 1/500) and ferritin or 
peroxidase-labeled rabbit anti-human IgG. The 
beads with the bound complexes were examined 
by electron microscopy. 
Production of antipeptide sera 
For the production of antisera, rabbits were 
inoculated subcutaneously with 1 ml of an emul- 
sion of 500 /~g resin-bound peptide of 
226-237/p24-HIV-1 with and without complete 
Freund's adjuvant in PBS. Booster injections were 
given at intervals of 4 weeks with and without 
incomplete Freund's adjuvant. Serum was taken 1 
week after the booster injections in each case and 
tested for antipeptide-specific antibodies in ELISA 
tests. In addition, the specificity of the rabbit sera 
was tested on Western blots for reactivity with 
p24 of HIV-1. HIV-l-infected H9 cells were 
solubilized and the proteins submitted to 
SDS-PAGE and Western blotting as described 
(Gi~rtler et al., 1987). 
Results 
Peptide synthesis 
Using chloromethylated polystyrene with the 
first amino acid bound in ester linkage to the 
resin, peptides were synthesized using orthogonal 
solid phase peptide synthesis with Fmoc-protected 
amino acids (Fig. 1). In order to stabilize the 
linkage to the resin for the treatment with sec- 
ondary amine to remove the Fmoc protection 
group and with trifluoroacetic acid to cleave the 
side-chain protection groups, amino acids with 
strong electron-donating (Phe, Leu) or electron-at- 
tracting (Arg, Lys) functions were avoided. In 
these experiments we selected alanine as the first 
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Fig. 1. Reaction steps used for the synthesis of carrier-bound 
peptides. X, permanent side chain protection group. R1, R2, 
R,, amino acid residues. 
amino acid with no functional side-chain which 
should have given an approximately equal distri- 
bution of electron density in the linkage group. 
The synthesized peptides were sequenced and 
found to have the correct amino acid sequences. 
From this sequencing data it could be concluded 
that the material was 90% pure (M. Eulitz, GSF 
Munich, personal communication). Since no fur- 
ther purification procedures were used, this degree 
of homogeneity was probably due to the double 
coupling of each residue and (with respect o HF 
or TFMSA cleavage) to the relatively mild treat- 
ment with diluted trifluoroacetic acid to remove 
the acid-labile side-chain protection groups. 
ELISA test systems 
The Millititer filtration system, with a hydro- 
philic Durapore membrane which was used for the 
ELISA tests was characterized by a very low pro- 
tein binding capacity. In order to block residual 
protein binding to the plastic wells or to the resin, 
both were incubated with a gelatin solution before 
the addition of the antisera. The amount of anti- 
gen necessary to obtain a positive signal was 
titrated using a positive human HIV-I serum pool 
and positive signals were still observed with 10 ng 
beads/well ( = ca. 5 ng of peptide). Because of the 
high substitution of beads with peptide, further 
tests were done with 1/~g beads (= ca. 500 ng of 
peptide) per well since at lower concentrations a 
statistically equal distribution of beads per well 
could not be ensured. 
In addition to the small amounts of specific 
peptide antigen sufficient for a positive reaction, 
the ELISA test using carrier-bound peptides 'in 
solution' could be completed in a very short time 
( -3  h); this was probably due to the optimal 
antigen presentation of the peptides on the surface 
of the carrier. For comparison, p655-667/gp41 
was synthesized using t-Boc chemistry and the 
peptide was cleaved with HF, purified and then 
coupled to ELISA plates in the traditional manner 
using sodium cabonate buffer (pH 9.5). Those 
tests showed a higher background and were found 
to be less sensitive and less specific. 
To demonstrate antigen-antibody complex for- 
mation on the surface of the beads, ferritin-labeled 
anti-human IgG was used as the second antibody 
and the beads were examined by electron mi- 
croscopy. Ferritin grains were observed to be 
localized in very dense concentrations on the car- 
rier surface and no grains could be seen inside the 
Fig. 2. Electronmicroscopy (x  100000) of peptide beads 226-237/p24 following reaction with an HIV-positive serum. A: using 
ferritin-labeled anti-human IgG as second antibody. B: using peroxidase-labeled anti-human IgG as second antibody. 
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TABLE I 
COMPARISON OF THE RESULTS OBTAINED WITH VARIOUS HIV-I-POSITIVE SERA IN AN ELISA USING CARRIER- 
BOUND PEPTIDE AND IN WESTERN BLOT EXPERIMENTS. 
Serum Peptide-ELISA Western-blot Comments 
p109-123/p17 p226-237/p24 p655-667/gp41 p17 p24 gp41 
1 1/200 1/200 1/400 + 
2 - 1/200 1/200 - 
3 1/400 1/200 1/100 + + 
4 - 1/400 1/200 - 
5 1/200 1/400 1/800 + 
6 1/200 1/400 1/400 + 
7 1/800 1/1600 1/400 + + 
8 - 1/100 1/1600 - 
9 1/200 1/400 1/800 + 
10 1/200 1/400 1/1600 + 
11 1/100 1/400 1/400 + 
12 1/100 1/400 1/200 + 
13 1/200 1/400 ( + ) 
14 1/400 1/800 - 
15 1/200 1/800 1/400 + + 
++ + 
+ + 
+ + ( + ) Early infection 
++ + 
( + ) + + AIDS 
++ ++ 
++ + 








beads (Fig. 2). This may have been due to the 
relatively large size of the ferritin-labeled antibody 
molecule. Using peroxidase-labeled anti-human 
IgG, the reaction appeared, in part, to be internal. 
HIV-1 positive sera taken from patients at differ- 
ent stages of the viral infection were titrated up to 
dilutions of 1/10000. Positive signals were ob- 
tained in the dilution range of 1/120 to 1/5000 
for the respective sera. The values of each individ- 
ual serum were compared with the results ob- 
tained from continuously used Western blot tests 
of HIV-1 positive sera from electrophoretically 
separated viral antigens; values for the ELISA test 
were found to coincide closely with the results 
from Western blots (Table 1). HIV-negative sera 
showed, in some cases, a background reaction up 
to dilutions of 1/40. 
Production of peptide-specific antisera 
Rabbits were inoculated with carrier-bound 
peptide p226-237/p24 alone or emulsified with 
Freund's adjuvant. Sera were taken 1 week after 
the booster injections and tested for anti-peptide- 
specific antibodies (Table II). The rabbits, inoc- 
ulated with peptide-antigen and Freund's ad- 
juvant developed antibodies after the first booster 
inoculation and showed higher anti-peptide titers. 
The sera were tested for their reactivity with the 
native antigen on Western blots; for these experi- 
ments HIV-1 proteins were separated by SDS- 
PAGE and transferred to nitrocellulose. The p24- 
specific band could be identified in all sera. For 
further confirmation of the specificity of the anti- 
body reaction, purified p24 produced by recombi- 
nant gene technology in bacteria (E. Soutschek- 
Bauer, M. Motz, personal communication) was 
coupled to ELISA plates. The sera of the rabbit 
inoculated with peptide beads in combination with 
Freund's adjuvant showed positive reactions in 
TABLE II 
ANTI-PEPTIDE TITERS OBTAINED IN RABBITS AFTER 
INOCULAT ION WITH CARRIER-BOUND PEPTIDE 
226-237/p24. SERUM WAS TAKEN 1 WEEK AFTER 
BOOSTER INJECTIONS IN EACH CASE AND TESTED 
FOR ANTI-PEPTIDE SPECIFIC ANTIBODIES. 
Time Rabbit 1 Rabbit 2 
(weeks after cartier-bound cartier-bound peptide 
inoculation) peptide in combination with 
Freund's adjuvant 
0 
5 1/16 1/32 
9 1/32 1/64 
13 1/160 1/320 
17 1/640 1/1280 
21 1/1 280 1/2  560 
dilutions up to 1/1000; sera from the rabbit im- 
munized without Freund's adjuvant could be 
titrated up to 1/500. 
Discussion 
Using a combination of 1% cross-linked poly- 
styrene resin with the first amino acid complex in 
ester linkage to the chlormethylated benzyl groups 
(as generally used in N-t-Boc peptide chemistry) 
and the addition of Fmoc-protected amino acids, 
it was possible to obtain pure peptides still con- 
nected to their solid support and with all side-chain 
blocking groups removed. Cleavage from the resin 
of peptides bound as benzyl esters has been shown 
to occur after treatment with 1% triflu0roacetic 
acid (Stewart and Young, 1984). However, in the 
present method the resin was heavily substituted 
with alanine (0.59 mmol /g  resin) as the first amino 
acid and the trifluoroacetic acid treatments did 
not result in a substantial loss of peptide from the 
resin. Similarly, the peptide-resin linkage was re- 
sistent to treatment with secondary amine to re- 
move Fmoc groups after each coupling step. In 
each case the sequences of the synthesized peptides 
were confirmed by amino acid analysis. 
After extensive washing of the resin-bound 
peptide it was possible to use the peptides without 
any further purification steps in diagnostic EL ISA 
tests for screening human sera for HIV-specific 
antibodies. In these test systems the antigens were 
presented in a way which may mimic their struc- 
ture in the native proteins. It is known that pro- 
tein-binding to plastic supports, which is done 
routinely at high pH values (pH 9.5), destroys the 
secondary structure of many antigens. This may 
be avoided by an ELISA test in solution with the 
antigens bound to the solid support at their 
carboxy-terminal ends. In addition to the optimal 
antigen presentation i  solution which permitted a
reduction of the antigen concentration to 5 ng 
peptide per well, it was possible to shorten all the 
incubation times and the total test could be per- 
formed in about 3 h. Furthermore, the antibody 
complexes could be removed from the peptide 
beads by treatment with detergent and re-used. 
In addition, we have shown that it is possible to 
raise specific antipeptide sera in rabbits without 
any further purification or coupling to other pro- 
tein material known to destroy most of the sec- 
ondary structure antigens. Polystyrene is a rather 
weak antigen and specific antipeptide sera were 
readily obtained after inoculation. 
The method described here is inexpensive and 
should permit rapid, simple diagnostic test sys- 
tems to be stablished for a wide range of infec- 
tious diseases. 
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